- Corealis Pharma Inc. inaugurates its expanded facilities in Laval’s Biotech City. The expansion, resulting from an investment of over $10 million, increases the company’s premises from 33,000 to 63,000 square feet.
Corealis Pharma Inc., a trusted name in the world of Contract Research and Development Organizations (CRO/CDMOs), today inaugurates its expanded facilities in Laval’s Biotech City. The expansion, a result of an investment exceeding $10 million, extends the premises of the Quebec-based company from 33,000 to 63,000 square feet. This expansion facilitates the installation of new state-of-the-art laboratories, marking a new era for Corealis, both within Quebec and globally.
“Today, we inaugurate these state-of-the-art laboratories. These facilities will bolster our research and development capabilities for new drugs, catering to global growth and enhancing our market presence,” stated Corealis President Yves Roy.
Established in 2005 by three pioneering scientists – Yves Roy, Patrick Gosselin, and Yves Mouget – Corealis swiftly garnered the trust of small and medium-sized biotechs globally, as well as major pharmaceutical entities. In 2022, to expedite its expansion, Corealis forged a partnership agreement with the CDPQ and Archimed, a global investment firm focused on healthcare industries. With a clientele predominantly located in New England and California, alongside various other regions worldwide, the company recorded a notable 20% increase in sales for 2023.
The new space will enable Corealis Pharma to expedite advancements in formulation development and manufacturing of oral solid dosage forms, early-stage projects, analytical method development, integration of state-of-the-art analytical and formulation equipment, the pace and scale of drug research and development, and expanded clinical trial material manufacturing and packaging.
The inauguration of Corealis’ new facilities today marks the realization of a three-stage strategic plan aimed at attaining the company’s primary objective: to emerge as the global benchmark in the development of oral solid dosage form formulations, thereby reinforcing Quebec’s status as a center of excellence in biotechnology. “Corealis elevates the profile of Quebec and the city of Laval, in particular. We take immense pride in supporting the directors and employees of this esteemed company, facilitating its continued growth on our soil, thus reaffirming Biotech City as a premier destination for investment and advancement in Quebec’s life sciences landscape,” concluded Laval City Councillor Christine Poirier.
Overview of outsourcing trends 
